echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > All you want to know about bevacizumab is here

    All you want to know about bevacizumab is here

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bevacizumab is a recombinant humanized monoclonal antibody that specifically targets and binds to human vascular endothelial growth factor (VEGF), inhibits the binding of VEGF to its receptor, inhibits tumor angiogenesis, and reduces tumor blood flow.


    Bevacizumab is a recombinant humanized monoclonal antibody that specifically targets and binds to human vascular endothelial growth factor (VEGF), inhibits the binding of VEGF to its receptor, inhibits tumor angiogenesis, and reduces tumor blood flow.


    1.


    1.


    • Indications for domestic medical insurance : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma


       

    • Indications for domestic instructions : including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and refractory, recurrent or metastatic cervical cancer


  • Indications for domestic medical insurance : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma


     

  • Indications for domestic medical insurance : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma


    Domestic Medical Insurance Indication Domestic Medical Insurance Indication : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma


  • Indications for domestic instructions : including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and refractory, recurrent or metastatic cervical cancer


  • Indications for domestic instructions : including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and refractory, recurrent or metastatic cervical cancer


    Domestic label indications Domestic label indications : including four major medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, refractory, recurrent or metastatic cervical cancer


    Figure 2 Treatment steps for patients taking antihypertensive drugs for the first time (source reference [1] [1] ) (2) The question of whether bevacizumab can be used for cancer maintenance therapy .
    (2) Questions about whether bevacizumab can be used for cancer maintenance therapy .
    Clinical studies have shown that maintenance therapy with bevacizumab alone or in combination with other chemotherapy drugs can effectively improve PFS and OS in advanced non-small cell lung cancer, advanced ovarian cancer , metastatic colorectal cancer, advanced breast cancer, etc.
    It is recommended that clinicians fully Weigh the patient's clinical benefits, adverse reactions, quality of life and economic situation, and adjust the treatment plan in a timely manner according to the principle of individualization .
    Quality of life in ovarian cancer (3) Concerning the safety of minor surgery during bevacizumab administration .
    (3) Concerning the safety of minor surgery during bevacizumab administration .
    Foreign studies have shown that if minor surgery (including central venous catheterization/catheter removal, thoracic drainage, oral surgery, biopsy, etc.
    ) is required during bevacizumab administration, 16-17 days of drug withdrawal may be required before surgery Transition, if bevacizumab treatment is continued after surgery, a 9-14 day surgical recovery period is required .
    References: [1] Tang Xinying, Kuang Zemin.
    Expert consensus on blood pressure management in ovarian and cervical cancer patients treated with bevacizumab : Interpretation of British expert recommendations in 2019.
    Rational Drug Use in China, 2020; 1: 11-15.
    Consensus interpret 

     
     

     


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.